GUMM - Eliminate the Common Cold Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Carl R. who wrote (2191)	2/5/2000 1:25:00 PM
From: DanZ	Read Replies (2) of 5582

Carl, Hank's criticism of the sample size is without merit because nobody knows what the sample size is. I view his criticism as simply trying to plant doubt in people's minds because he is short GUMM. He has a habit of trying to find something negative in everything whether anything negative even exists. You think that this is good; I think that it hurts his credibility. Hank never has anything good to say about Gum Tech and doesn't give the company credit where credit is due. I have a hard time taking anybody serious that characterizes Zicam as "Ziscam" or "snake oil", or somebody that refuses to acknowledge that expectations for future fundamentals move stock prices to a much greater extent than past history. People that are apparently experienced with statistics posted that a sample size of 100 is statistically significant in this case. Quigley's independent study on 100 subjects was published in the Annals of Internal Medicine. I don't think that their study would have been accepted for publication if the results weren't statistically significant. A recent news story medformation.com said that the study on Zicam was conducted at four locations. Estimates are that up to 70% of colds are caused by the rhinovirus, and it is already known that all the serotypes of the rhinovirus use the ICAM-1 to infect cells. Based on Zicam's theoretical mechanism of action, it would be effective on all serotypes of rhinovirus, but not on viruses that don't infect cells through ICAM-1. We won't know until the details of the study are released if they proved the mechanism. If they didn't prove the mechanism with the last study, I think that they will try to prove it in a future study. As for Hank's attitude, everybody deserves a second chance, and people have some control over how others perceive them. I hope that you feel better soon, and thanks for the prognosis of how Zicam is treating your cold. You're right that it won't work for every cold, and I also wonder what consumers will think if it doesn't help every time. I asked the company about this a while back and they told me that they haven't received any complaints in this regard. Dan

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next